Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report

dc.contributor.authorRamos, German. E. E.
dc.contributor.authorCaglevic, Christian
dc.contributor.authorBulnes, Juan. F. F.
dc.contributor.authorPanay, Sergio. E. E.
dc.contributor.authorZapata, Mario. I. I.
dc.contributor.authorDaniele, Andres J.
dc.contributor.authorRodriguez, Manuel. E. E.
dc.date.accessioned2025-01-20T21:01:16Z
dc.date.available2025-01-20T21:01:16Z
dc.date.issued2022
dc.description.abstractEndothelial Growth Factor Receptor (EGFR) mutations are frequently found among NSCLC patients. Second-generation Tyrosine Kinase Inhibitor (TKI) Afatinib is frequently used in this population of patients achieving better results than cytotoxic chemotherapy in terms of survival and progression. Afatinib-related cardiotoxicity has been rarely reported. Here we comment on a clinical case of a Takotsubo Cardiomyopathy Afatinib-induced in an NSCLC patient.
dc.fuente.origenWOS
dc.identifier.doi10.3389/fcvm.2022.1060813
dc.identifier.issn2297-055X
dc.identifier.urihttps://doi.org/10.3389/fcvm.2022.1060813
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/92848
dc.identifier.wosidWOS:000893774000001
dc.language.isoen
dc.revistaFrontiers in cardiovascular medicine
dc.rightsacceso restringido
dc.subjectTakotsubo (stress) cardiomyopathy
dc.subjectAfatinib
dc.subjectEGFR mutation
dc.subjecttyrosine kinase inhibition
dc.subjectNSCLC
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleTakotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
dc.typeartículo
dc.volumen9
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files